Company news

Pelthos Therapeutics Inc. news in 2025

Pelthos Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

December 23, 2025

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI Topical Gel, 10.3%

December 5, 2025

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

December 4, 2025

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

December 2, 2025

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

November 13, 2025

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

November 7, 2025

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

November 5, 2025

Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum

October 9, 2025

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

September 8, 2025

Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference

September 2, 2025

Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

August 18, 2025

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

July 10, 2025

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

July 2, 2025

Decks in 2025